Abstract
Chronic hepatitis B is a serious and often progressive liver disorder for which there is no accepted therapy. Several small clinical trials have suggested that interferon may be helpful in the management of this condition, but most of these studies were uncontrolled, and the interpretation of the data is complicated by variations in dose schedules, major disparities in patient characteristics, and substantial differences in rates of spontaneous seroconversion of hepatitis B e antigen (HBeAg) in untreated controls.
1
,
2
A small, controlled clinical trial showed that 16 weeks of treatment with recombinant interferon alfa-2b resulted in the clearance of HBeAg in approximately . . .
